RENALYTIX**AI**

6 February 2019

<div align="center">

Renalytix AI plc
("**RenalytixAI**" or the "**Company**")

**RenalytixAI Expands Leadership Team to Support Launch
of AI-Enabled Diagnostics for Kidney Disease**

*Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and
Regulatory Programmes*

</div>

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the expansion of its leadership team with the appointment of Patti Connolly as vice president of clinical and scientific affairs and Paul Brenner, Ph.D. to the Advisory Board.

As vice president of clinical and scientific affairs, Patti Connolly is leading RenalytixAI's recruitment efforts for the prospective clinical utility study for its lead diagnostic, *KidneyIntelX*, which is scheduled to start in Q4 2019.

Patti Connolly brings over two decades of leadership experience in clinical research and development, the past ten years of which have focused on managing successful clinical trials as well as domestic and international regulatory affairs initiatives. Most recently, Patti Connolly served as clinical services director at Pearl Pathways where she was responsible for all clinical services operations, the full-service contract research organisation and the institutional review board. Patti Connolly received a bachelor's degree in Microbiology, and a master's degree in Pathology and Laboratory Medicine from Indiana University.

RenalytixAI also announces the addition of Paul Brenner, a computer science faculty member at the University of Notre Dame and Associate Director of Notre Dame's Center for Research Computing, to its Advisory Board. Paul Brenner contributes deep expertise in advanced computation, artificial intelligence and cyber security to the RenalytixAI Advisory Board. In his role at the University of Notre Dame, Mr Brenner advances computation-based research through cyber system security, design, deployment and operation, and directs a team of technical experts in the operation of high-performance computing hardware and software infrastructure for an active user base of over 2,000 researchers. Mr Brenner also serves as a Senior Reserve Advisor to the Air Force Cyber College Commandant (AFCC). In this capacity he advises the AFCC leadership on military reserve matters and leads the provision of technical and operational capabilities to AFCC. Mr Brenner received his bachelor's degree in Civil Engineering from the University of Notre Dame, a master's in Materials Science and Engineering from Ohio State University, and a doctoral degree in Computer Science and Engineering from University of Notre Dame.

For further information, please contact:

Renalytix AI plc	www.renalytixai.com
James McCullough, CEO	**Via Walbrook PR or Tel: +1 646 397 3970**

N+1 Singer (Nominated Adviser & Broker)	**Tel: 020 7496 3000**
Aubrey Powell / James White / George Tzimas (Corporate Finance)	
Tom Salvesen / Mia Gardner (Corporate Broking)	

Walbrook PR Limited	**Tel: 020 7933 8780** or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne	Mob: 07980 541 893 / 07584 391 303

About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room

without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.